Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease

被引:23
|
作者
Anglada-Huguet, Marta [1 ,2 ]
Giralt, Albert [1 ,2 ]
Perez-Navarro, Esther [1 ,2 ]
Alberch, Jordi [1 ,2 ]
Xifro, Xavier [1 ,2 ,3 ]
机构
[1] Univ Barcelona, Fac Med, Dept Biol Cel Lular Immunol & Neurociencies, Barcelona 08036, Spain
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
[3] Univ Girona, Fac Med, Dept Ciencies Med, Girona, Spain
关键词
huntingtin; immediate early genes; knock-in cells; neuroprotection; R6; mouse; transcription; IN STRIATAL CELLS; KINASE SIGNALING PATHWAY; TERNARY COMPLEX FACTORS; EARLY GENE INDUCTION; PROTEIN-KINASES; TRANSCRIPTION FACTORS; MAP KINASES; NEUROTROPHIC FACTOR; TRANSGENIC MICE; MOUSE MODEL;
D O I
10.1111/j.1471-4159.2012.07711.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The transcription factor Elk-1 has been revealed as neuroprotective against toxic stimuli. In this study, we explored the neuroprotective capacity of Elk-1 in Huntingtons disease. To this aim, we used two exon-1 mutant huntingtin (mhtt) mouse models (R6/1 and R6/2), and a full-length mhtt striatal cell model (STHdhQ111/Q111). Analysis of Elk-1 and pElk-1Ser383 in the striatum of R6 mice revealed increased levels during the disease progression. Similarly, Elk-1 and pElk-1Ser383 levels were increased in STHdhQ111/Q111 cells when compared with wild-type cells. In addition, we observed a predominant nuclear localization of Elk-1 in STHdhQ111/Q111 cells, and in the striatum of 30-week-old R6/1 mice. Nuclear Elk-1 did not colocalize with mhtt aggregates, suggesting a higher transcriptional activity. In agreement, the knock-down of Elk-1 decreased immediate early genes expression in STHdhQ111/Q111 cells, but not in wild-type cells. Interestingly, reduction of Elk-1 levels by siRNAs transfection promoted cell death and caspase 3 cleavage in STHdhQ111/Q111 cells, but not in wild-type cells. In summary, we propose that increased protein levels, phosphorylation and nuclear localization of Elk-1 observed in exon-1 and full-length Huntingtons disease models could be a compensatory mechanism activated by striatal cells in response to the presence of mhtt that contributes to neuroprotection.
引用
收藏
页码:639 / 648
页数:10
相关论文
共 50 条
  • [1] SENP1 participates in the dynamic regulation of Elk-1 SUMOylation
    Witty, James
    Aguilar-Martinez, Elisa
    Sharrocks, Andrew D.
    BIOCHEMICAL JOURNAL, 2010, 428 : 247 - 254
  • [2] Meclizine is neuroprotective in models of Huntington's disease
    Gohil, Vishal M.
    Offner, Nicolas
    Walker, James A.
    Sheth, Sunil A.
    Fossale, Elisa
    Gusella, James F.
    MacDonald, Marcy E.
    Neri, Christian
    Mootha, Vamsi K.
    HUMAN MOLECULAR GENETICS, 2011, 20 (02) : 294 - 300
  • [3] Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington's disease
    Yildirim, Ferah
    Ng, Christopher W.
    Kappes, Vincent
    Ehrenberger, Tobias
    Rigby, Siobhan K.
    Stivanello, Victoria
    Gipson, Theresa A.
    Soltis, Anthony R.
    Vanhoutte, Peter
    Caboche, Jocelyne
    Housman, David E.
    Fraenkel, Ernest
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (49) : 24840 - 24851
  • [4] Neuroprotective possibilities for Huntington's disease
    Emerich, DF
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) : 467 - 479
  • [5] Transcriptional Activation of REST by Sp1 in Huntington's Disease Models
    Ravache, Myriam
    Weber, Chantal
    Merienne, Karine
    Trottier, Yvon
    PLOS ONE, 2010, 5 (12):
  • [6] Sequential activation of Elk-1/Egr-1/GADD45α by arsenic
    Shi, Qiwen
    Sutariya, Vijaykumar
    Bishayee, Anupam
    Bhatia, Deepak
    ONCOTARGET, 2014, 5 (11) : 3862 - 3870
  • [7] Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets
    Jiang, Mali
    Wang, Jiawei
    Fu, Jinrong
    Du, Lin
    Jeong, Hyunkyung
    West, Tim
    Xiang, Lan
    Peng, Qi
    Hou, Zhipeng
    Cai, Huan
    Seredenina, Tamara
    Arbez, Nicolas
    Zhu, Shanshan
    Sommers, Katherine
    Qian, Jennifer
    Zhang, Jiangyang
    Mori, Susumu
    Yang, X. William
    Tamashiro, Kellie L. K.
    Aja, Susan
    Moran, Timothy H.
    Luthi-Carter, Ruth
    Martin, Bronwen
    Maudsley, Stuart
    Mattson, Mark P.
    Cichewicz, Robert H.
    Ross, Christopher A.
    Holtzman, David M.
    Krainc, Dimitri
    Duan, Wenzhen
    NATURE MEDICINE, 2012, 18 (01) : 153 - 158
  • [8] Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease
    Scotter, E. L.
    Goodfellow, C. E.
    Graham, E. S.
    Dragunow, M.
    Glass, M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (03) : 747 - 761
  • [9] Exploration of neuroprotective mechanism of GLP-1 in animal models with Alzheimer's disease
    Li, Jingxin
    Wei, Yafen
    Yin, Ping
    Liu, Li
    Lu, Chong
    Gong, Zhenzhong
    Wu, Shanshan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (04): : 3897 - 3904
  • [10] Neuroprotective Effects of Phytocannabinoid-Based Medicines in Experimental Models of Huntington's Disease
    Sagredo, Onintza
    Pazos, M. Ruth
    Satta, Valentina
    Ramos, Jose A.
    Pertwee, Roger G.
    Fernandez-Ruiz, Javier
    JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (09) : 1509 - 1518